A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use

Trial Profile

A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2017

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications NSAID-induced ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms LAVENDER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 06 Nov 2012 Primary endpoint 'Time-to-disease-recurrence' has been met.
    • 22 Jun 2012 The results of this trial were used to support approval of esomeprazole in Japan for prevention of ulcer reccurence in aspirin users.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top